Dr. Jonathan Rothberg is a man who needs little introduction, and is now receiving the Association of Molecular Pathology’s (AMP) Award for Excellence in Molecular Diagnostics Services. We spoke to him about his many achievements, his proudest moments, and the future of his fascinating field.
Given that Front Line Genomics was started after its founder’s father was diagnosed with Mesothelioma, it’s naturally a cause that we care passionately about. To that end we sat down with the Mesothelioma Cancer Alliance (MCA), an organisation dedicated to providing resources, information, and support to individuals suffering from mesothelioma and other asbestos-related diseases and their families, to find out more about the great work they do and the challenges they face every day.
While the Annual Meeting & Expo is the pinnacle of the association’s educational calendar, AMP offers educational initiatives throughout the year in a variety of formats, many of which offer continuing education credit.
AMP 2018: Decoding the Cancer Genome: Breakthrough AI Technology Quickly Identifies Actionable Mutations
Explosive advances in next-generation sequencing (NGS) have greatly improved the ability to identify actionable cancer mutations, both for solid and hematological malignancies, and sparked a new era of oncology care. But accurate analysis and proper interpretation of the complex genomic data produced by NGS remain key hurdles.
The Association for Molecular Pathology (AMP) Annual Meeting & Expo is where the molecular diagnostics community gathers to advance clinical knowledge, discuss new discoveries, share recent successes, and showcase the latest technological advances in molecular medicine.
We are seeking to explore the true story of AI: where are we now, what do we need to overcome, and how should we integrate this technology within the genomics sphere?
The Greenwood Genetic Center (GGC) has embarked on a novel program to leverage traditional and emerging genomic technologies, in the search for answers for undiagnosed patients.
We take a look at the advantages of securing a deeper access to data.
The All of Us Research Program is a key element of the Precision Medicine Initiative. Two years on, we take a look at what they have achieved, and how they plan on integrating their research into the U.S. healthcare system over the next ten years.
Kat Arney is one of the “Top 10 Brits who make science sexy”, according to BBC America. Need we say more?
“How Can We Anticipate and Respond to Technologies and Information That is Rapidly Changing?” – Josephine Johnston
Josephine Johnston is an expert on the ethical, legal and policy implications of biomedical technologies, particularly as used in human reproduction, psychiatry, genetics, and neuroscience.
“I Would Like to See Widespread Reimbursement of Clinical Genomic Testing as Well as Screening” – Gavin Stone
Gavin Stone is an electronics engineer who joined Edico Genome in 2013 to lead corporate development and marketing for the DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics chip to massively speed up genomic medicine.
“It’s Through Community Outreach & Education We Ensure Continued Public Commitment” – Hsiao-Tuan Chao
Hsiao-Tuan Chao is a physician-scientist in the field of child neurology, we’ve had a chat with her in this week’s Short Read.
“I’d Like to See Our Understanding of at Least One More Disease Transformed by Genomics and Big Data” – Jeremy Grushcow
Combining over 15 years’ experience with pharma and life sciences businesses with a passion for participant-centric research, Jeremy Grushcow is CBO at Sequence Bio, where he saw a once-in-in a lifetime opportunity to change how we treat, prevent and understand disease.
“The Disconnect Between the ‘Promise’ and the ‘Actual Impact’ is the Biggest Challenge in -Omics Based Technologies” – Zisis Kozlakidis
We’ve sat down with Dr Zisis Kozlakidis before his talk ‘Tracking Viruses in Space and Time’ at the Festival of Genomics in London 2018, were we talk virus.